Zyprexa drives Lilly's growth in Japan
This article was originally published in Scrip
Executive Summary
Sales at Lilly's Japanese operation edged up by 2% to ¥91.8 billion ($936.7 million) last year, a solid increase for mainstay product Zyprexa (olanzapine) helping to offset some weakness elsewhere in the portfolio.